| HOME >> BIOLOGY >> TECHNOLOGY |
Clark A. Johnson, who has been a director of Neurologix since February 2004, stepped down as Vice Chairman, President and CEO upon Mr. Adams's and Mr. Koven's arrivals. Martin J. Kaplitt, M.D., who was a founder and has been a member of the Board since November 1999, relinquished his position as Board Chairman upon Mr. Adams's assumption of such role. Both Mr. Johnson and Dr. Kaplitt will remain on the Board of Directors.
"We thank Clark for his leadership of Neurologix and his successful stewardship of NLX-P101 as the Company completed the first successful Phase 2 study of a gene therapy product for Parkinson's disease," said Dr. Kaplitt. "We are excited and hopeful that the experienced leadership provided by Mr. Adams and Mr. Koven will help Neurologix secure the additional financing needed to carry out the Company's planned operations and business activities as we continue to pursue new and, potentially, exciting milestones in the development of gene therapy treatments for patients in urgent need."
About Neurologix
Neurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are l
'/>"/>
| SOURCE Neurologix, Inc. Copyright©2010 PR Newswire. All rights reserved |